KINIKSA PHARMACEUTICALS, LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.68 USD | +3.42% |
|
+4.31% | +0.80% |
| Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
| Apr. 23 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
Financials (USD)
| Sales 2024 * | 385M | Sales 2025 * | 519M | Capitalization | 1.25B |
|---|---|---|---|---|---|
| Net income 2024 * | 6M | Net income 2025 * | -19M | EV / Sales 2024 * | 2.61 x |
| Net cash position 2024 * | 242M | Net cash position 2025 * | 386M | EV / Sales 2025 * | 1.66 x |
| P/E ratio 2024 * |
-37
x | P/E ratio 2025 * |
-38.3
x | Employees | 297 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kiniksa Pharmaceuticals, Ltd.
More recommendations
More press releases
| 1 day | +3.42% | ||
| 1 week | +4.31% | ||
| Current month | -10.39% | ||
| 1 month | -11.42% | ||
| 3 months | -3.65% | ||
| 6 months | +15.33% | ||
| Current year | +0.80% |
1 week
16.56
18.14
1 month
16.5620.32
Current year
16.5622.09
1 year
10.6522.09
3 years
7.3622.09
5 years
5.0128.67
10 years
5.0132.88
| Managers | Title | Age | Since |
|---|---|---|---|
Eben Tessari
FOU | Founder | 42 | 15-06-30 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 15-06-30 |
Mark Ragosa
DFI | Director of Finance/CFO | 50 | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 15-09-30 |
Barry D. Quart
BRD | Director/Board Member | 67 | 15-09-30 |
Thomas Malley
BRD | Director/Board Member | 55 | 16-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% | ||
| 0.05% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 17.1 | +1.09% | 361,220 |
| 24-04-19 | 16.91 | +0.18% | 375,954 |
| 24-04-18 | 16.88 | -0.41% | 409,188 |
| 24-04-17 | 16.95 | -2.92% | 389,307 |
| 24-04-16 | 17.46 | +0.11% | 304,967 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.1
USD
Average target price
28.2
USD
Spread / Average Target
+64.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.80% | 1.21B | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- KNSA Stock
